President Donald Trump announced that convalescent plasma would continue as a therapeutic drug for COVID-19. Several days ago weak data from randomized control trials raised concerns as to whether the treatment would receive emergency authorization.
The Carlyle Group has plasma play MAK Systems, a blood products software company. Carlyle's Piramal Pharma Solutions makes antibody drug conjugate.
I expect Carlyle lobbied hard to overcome NIH's recommending the FDA delay allowing the use of convalescent plasma. Carlyle co-founder David Rubenstein's phone call is one any U.S. President would take.
The day before Trump's announcement he attacked deep state operatives in the FDA for holding up treatments and vaccines.
